Stem Cell Delivery of Therapies for Brain Disorders

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2014 Aug 7

PMID 25097727

Citations 41

Authors

Alexander Aleynik

Kevin M Gernavage

Yasmine Sh Mourad

Lauren S Sherman

Katherine Liu

Yuriy A Gubenko

Pranela Rameshwar

Affiliations

Soon will be listed here.

Abstract

The blood brain barrier (BBB) poses a problem to deliver drugs for brain malignancies and neurodegenerative disorders. Stem cells such as neural stem cells (NSCs) and mesenchymal stem cells (MSCs) can be used to delivery drugs or RNA to the brain. This use of methods to bypass the hurdles of delivering drugs across the BBB is particularly important for diseases with poor prognosis such as glioblastoma multiforme (GBM). Stem cell treatment to deliver drugs to neural tumors is currently in clinical trial. This method, albeit in the early phase, could be an advantage because stem cells can cross the BBB into the brain. MSCs are particularly interesting because to date, the experimental and clinical evidence showed 'no alarm signal' with regards to safety. Additionally, MSCs do not form tumors as other more primitive stem cells such as embryonic stem cells. More importantly, MSCs showed pathotropism by migrating to sites of tissue insult. Due to the ability of MSCs to be transplanted across allogeneic barrier, drug-engineered MSCs can be available as off-the-shelf cells for rapid transplantation. This review discusses the advantages and disadvantages of stem cells to deliver prodrugs, genes and RNA to treat neural disorders.

Citing Articles

Advances in Stem Cell Therapy for Huntington's Disease: A Comprehensive Literature Review.

Shah S, Mansour H, Lucke-Wold B Cells. 2025; 14(1.

PMID: 39791743 PMC: 11719515. DOI: 10.3390/cells14010042.

A Systematic Review of Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential Treatment for Glioblastoma.

Agosti E, Antonietti S, Ius T, Fontanella M, Zeppieri M, Panciani P Brain Sci. 2024; 14(11).

PMID: 39595821 PMC: 11591642. DOI: 10.3390/brainsci14111058.

Transplantation of autologous mesenchymal stromal cells in complete cervical spinal cord injury: a pilot study.

Macedo C, Souza B, Villarreal C, Silva D, da Silva K, de Souza C Front Med (Lausanne). 2024; 11:1451297.

PMID: 39328312 PMC: 11424397. DOI: 10.3389/fmed.2024.1451297.

Focusing on mitochondria in the brain: from biology to therapeutics.

Song N, Mei S, Wang X, Hu G, Lu M Transl Neurodegener. 2024; 13(1):23.

PMID: 38632601 PMC: 11022390. DOI: 10.1186/s40035-024-00409-w.

Mesenchymal Stem Cell-Macrophage Crosstalk Provides Specific Exosomal Cargo to Direct Immune Response Licensing of Macrophages during Inflammatory Responses.

Naaldijk Y, Sherman L, Turrini N, Kenfack Y, Ratajczak M, Souayah N Stem Cell Rev Rep. 2023; 20(1):218-236.

PMID: 37851277 DOI: 10.1007/s12015-023-10612-3.

References

Danks M, Yoon K, Bush R, Remack J, Wierdl M, Tsurkan L . Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res. 2007; 67(1):22-5. DOI: 10.1158/0008-5472.CAN-06-3607. View

Coolen M, Katz S, Bally-Cuif L . miR-9: a versatile regulator of neurogenesis. Front Cell Neurosci. 2013; 7:220. PMC: 3834235. DOI: 10.3389/fncel.2013.00220. View

Helms J, Zurzolo C . Lipids as targeting signals: lipid rafts and intracellular trafficking. Traffic. 2004; 5(4):247-54. DOI: 10.1111/j.1600-0854.2004.0181.x. View

Gonzalez-Gomez P, Sanchez P, Mira H . MicroRNAs as regulators of neural stem cell-related pathways in glioblastoma multiforme. Mol Neurobiol. 2011; 44(3):235-49. DOI: 10.1007/s12035-011-8196-y. View

Yankner B, Duffy L, Kirschner D . Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990; 250(4978):279-82. DOI: 10.1126/science.2218531. View

Bruder S, Fink D, Caplan A . Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem. 1994; 56(3):283-94. PMC: 7166813. DOI: 10.1002/jcb.240560303. View

Lim J, Park S, Kim S, Jun J, Oh J, Ryu C . Neural differentiation of brain-derived neurotrophic factor-expressing human umbilical cord blood-derived mesenchymal stem cells in culture via TrkB-mediated ERK and β-catenin phosphorylation and following transplantation into the developing brain. Cell Transplant. 2011; 20(11-12):1855-66. DOI: 10.3727/096368910X557236. View

Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts A . Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008; 2(2):141-50. DOI: 10.1016/j.stem.2007.11.014. View

Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P . Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 2010; 90(2):144-55. DOI: 10.1038/labinvest.2009.126. View

10.

Liu H, Fan C, Ting C, Yeh C . Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview. Theranostics. 2014; 4(4):432-44. PMC: 3936295. DOI: 10.7150/thno.8074. View

11.

Liu L, Eckert M, Riazifar H, Kang D, Agalliu D, Zhao W . From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier?. Stem Cells Int. 2013; 2013:435093. PMC: 3753739. DOI: 10.1155/2013/435093. View

12.

Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang Y . MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 2010; 1359:14-21. DOI: 10.1016/j.brainres.2010.08.074. View

13.

Ryu C, Park K, Hou Y, Jeong C, Kim S, Jeun S . Gene therapy of multiple sclerosis using interferon β-secreting human bone marrow mesenchymal stem cells. Biomed Res Int. 2013; 2013:696738. PMC: 3654641. DOI: 10.1155/2013/696738. View

14.

Larrue V, von Kummer R R, Muller A, Bluhmki E . Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001; 32(2):438-41. DOI: 10.1161/01.str.32.2.438. View

15.

Zhang C, Han L, Zhang A, Yang W, Zhou X, Pu P . Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells. Int J Oncol. 2010; 36(6):1503-12. DOI: 10.3892/ijo_00000637. View

16.

Choi S, Lee J, Wang K, Phi J, Song S, Song J . Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. Eur J Cancer. 2011; 48(1):129-37. DOI: 10.1016/j.ejca.2011.04.033. View

17.

Glenner G, Wong C . Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. 1984. Biochem Biophys Res Commun. 2012; 425(3):534-9. DOI: 10.1016/j.bbrc.2012.08.020. View

18.

Munoz J, Rodriguez-Cruz V, Greco S, Ramkissoon S, Ligon K, Rameshwar P . Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis. 2014; 5:e1145. PMC: 3973225. DOI: 10.1038/cddis.2014.111. View

19.

Pardridge W, Boado R . Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 2012; 503:269-92. DOI: 10.1016/B978-0-12-396962-0.00011-2. View

20.

Tzeng S, Green J . Therapeutic nanomedicine for brain cancer. Ther Deliv. 2013; 4(6):687-704. PMC: 3838881. DOI: 10.4155/tde.13.38. View